Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD4<sup>+</sup> T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.

Science translational medicine·2026
Same author

Regional patterns of grey matter volume decline in relapsing-remitting multiple sclerosis relative to healthy ageing.

NeuroImage·2026
Same author

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

The New England journal of medicine·2026
Same author

Alpha-linolenic acid associations with disability and brain volume in multiple sclerosis: a brief replication report.

Frontiers in neurology·2026
Same author

Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study.

BMJ neurology open·2026
Same author

NorTrials drives growth in Norwegian clinical trials.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Related Experiment Video

Updated: Jun 22, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Vitamin D treatment in multiple sclerosis.

Kjell-Morten Myhr1

  • 1Department of Neurology, Haukeland University Hospital, Norwegian Multiple Sclerosis National Competence Centre, Bergen, Norway. kjell-morten.myhr@helse-bergen.no

Journal of the Neurological Sciences
|June 25, 2009
PubMed
Summary

Vitamin D may influence multiple sclerosis (MS) risk and activity. Supplementation might reduce MS development, conversion from initial events, and relapse rates in relapsing-remitting MS patients.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jun 22, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neuroimmunology
  • Endocrinology

Background:

  • Multiple sclerosis (MS) is an immune-mediated central nervous system disorder.
  • Genetic and environmental factors contribute to MS etiology.
  • Vitamin D is a key environmental factor investigated for its role in MS.

Purpose of the Study:

  • To evaluate the influence of vitamin D on MS susceptibility and disease activity.
  • To assess the potential benefits of vitamin D supplementation in MS prevention and management.

Main Methods:

  • Review of epidemiological evidence.
  • Analysis of clinical and laboratory data.
  • Examination of experimental animal models.

Main Results:

  • Evidence suggests vitamin D influences MS susceptibility and clinical disease activity.
  • Vitamin D supplementation may lower the risk of developing MS.
  • Intervention may reduce conversion to clinically definite MS and decrease relapse rates in relapsing-remitting MS.

Conclusions:

  • Vitamin D plays a potential role in multiple sclerosis.
  • Further research is needed to establish optimal vitamin D dosage, serum levels, target populations, and intervention timing.